Key result
Anticholinergic drug use at hospital admission linked to ~27% higher overall mortality.
Why the study?
Use of drugs with anticholinergic properties has a negative impact on older people, but their association with mortality in older hospitalized patients required investigation.
Does the use of drugs with anticholinergic properties at hospital admission increase mortality in older patients?
Cohort (n=74,589)
Yes
Does the use of drugs with anticholinergic properties at hospital admission increase mortality in older patients?
Answers are grounded in this paper and cite their sources.
The use of drugs with anticholinergic properties at hospital admission is independently associated with increased short- and long-term all-cause mortality in older geriatric patients.
BACKGROUND: Use of drugs with anticholinergic properties (DAP) has a negative impact on older people. OBJECTIVE: Our aim was to examine the association between DAP at hospital admission and mortality in older patients. PATIENTS AND METHODS: We performed a nationwide population-based cohort study including patients aged ≥ 65 years admitted to Danish geriatric medicine departments during 2005-2014. National health registers were used to link with individual-level data. Patients were followed to emigration, death, or study termination (31 December 2015). DAP was defined as medications included in the anticholinergic cognitive burden (ACB) scale, which assigns each DAP a score between 1 and 3. The individual ACB score was calculated and the number of DAP counted. We used Cox proportional-hazard regressions to estimate the crude and adjusted hazard ratios adjusting for age, activities of daily living, marital status, index admission period, BMI, and prior hospitalizations (model 1), and additionally Charlson Comorbidity Index (model 2). RESULTS: We included 74,589 patients aged (median [IQR]) 83 (77-88) years. Use of one or more DAP (62.5%) was associated with increased mortality compared with those with no use (p < 0.001). In the fully adjusted model 2, compared with no use, higher mortality risks (HR [95% CI]) were seen with ACB score of 2 and number of DAP ≥ 5 for 30-day (1.46 [1.32-1.61] and 1.46 [1.09-1.95]), 1-year (1.34 [1.28-1.41] and 1.48 [1.29-1.70]), and overall mortality (1.27 [1.23-1.31] and 1.44 [1.31-1.59]), respectively. CONCLUSIONS: Use of DAP at hospital admission is associated with short- and long-term mortality in geriatric patients. Deprescribing studies are warranted to study whether the impact on mortality can be attenuated.
No takes yet. Share an insight, caveat, or question.
Sørensen et al. (2021) conducted a cohort in Acutely hospitalized geriatric patients (n=74,589). Drugs with anticholinergic properties (DAP) vs. No use of DAP was evaluated on Overall mortality (HR 1.27, 95% CI 1.23-1.31, p=<0.001). Use of drugs with anticholinergic properties at hospital admission was significantly associated with increased overall mortality, with an anticholinergic cognitive burden score of 2 increasing the risk by 27% (HR 1.27) compared to no use.
Synapse has enriched 10 related papers. Consider them for comparative context: